| |
Consumers are looking to improve their gut health and direct-to-consumer testing companies are investing in the opportunity. Discover key considerations and learn how to pick the best at-home fecal collection device in this free guide. Download Now.
|
|
Today's Big NewsJan 25, 2023 |
|
Phreesia Life Sciences surveyed more than 4,300 patients checking in for their doctors’ appointments to better understand their perceptions and
preferences around clinical trials. But what's the best way to reach them? View Infographic
|
|
| By Max Bayer Entering his third year on the job, Roivant CEO Matt Gline is pushing back against the company's reputation as a discard company fishing for projects to rebuild. |
|
|
|
By Angus Liu Moderna and BioNTech recently reported positive early clinical data for their mRNA cancer vaccine in partnership with PD-1/L1 inhibitors. But as over a decade of research has failed to transpire into approved therapies, several biopharma executives remain on the fence about the future of these vaccines future, while others believe the field is getting closer to finding its sweet spot. |
By Nick Paul Taylor Vertex and CRISPR Therapeutics have taken a small step toward a landmark approval, securing European Medicines Agency (EMA) validation of the approval application for their CRISPR-Cas9 candidate. |
Sponsored by Clarify Health We initiate a discussion focused on the relation of clinical trials and the need for geographical inclusion versus societal exclusivity. With some trial sites including only 20% of the disease population in the United States, innovation is needed. |
By Nick Paul Taylor Cidara Therapeutics has overcome the uncertainties raised by the FDA’s advisory committee to receive near-unanimous backing for its antifungal drug, boosting the prospects of the therapy winning approval in March. |
By Annalee Armstrong After a brief 2.5-month hold, Inhibikase Therapeutics’ Parkinson’s disease therapy is heading back to the clinic. |
By Gabrielle Masson Dimension debuted dramatically today as the first sector specialist firm taking aim at the intersection of tech and the life sciences. With an oversubscribed fund of $350 million in hand, the VC touts the lofty goal of bridging the gap between the present and the future. |
By James Waldron Two years after signing a collab with Takeda, KSQ Therapeutics has garnered interest from another Japanese pharma. This time it’s Ono Pharmaceutical, which is handing over a “double-digit million” upfront payment for a number of preclinical oncology programs. |
By Fraiser Kansteiner On April 3, George Scangos, Ph.D., who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. |
By Andrea Park More than two years after submitting it for FDA review, Tidepool has scored the agency’s clearance for a smartphone app that allows people with Type 1 diabetes to build their own closed-loop “artificial pancreas” system. |
By Frank Diamond Deaths from cardiovascular disease climbed to their highest levels ever in 2020, according to the American Heart Association, reflecting the indirect and direct effects of COVID-19. |
By Eric Sagonowsky Horizon Therapeutics CEO Tim Walbert has made routine appearances in rankings of the biopharma industry's best-paid executives, and he's set to collect once again with his company's sale to Amgen. |
By Teresa Carey In this week's episode of "Podnosis," we take you inside Fierce's JPM Week event. Listen in on snippets from a panel on what big retailers have to gain by moving into healthcare. And hear from Ramita Tandon about Walgreens' strategy around drug development. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we take you inside Fierce's JPM Week event. Listen in on snippets from a lively panel discussion on how companies will navigate the drug pricing policies the Biden administration rolled out just last year. And hear from Christine Roth, head of Bayer's oncology strategic business unit, about the company's plans to become a strong competitor in cancer. |
|
|---|
|
|
|
March 14-15, 2023 | San Francisco, CA Be in the room with the life sciences industry leaders to forge new connections & take advantage of in-person networking opportunities. Register now to be in the room for this amazing networking opportunity!
|
|
| RCTs with digital twins require fewer control patients and shorten trial timelines for Alzheimer's disease. Sponsored by: Unlearn AI |
What makes nucleotides suitable for current good manufacturing practices? Sponsored by: Thermo Fisher Scientific |
| This paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
